Abstract
In Europe, epoetin subsequent entry biologics (SEBs) have been in use since 2007. Canadian patents of erythropoietin stimulating agents are expiring in 2014, therefore it is predicted that epoetin SEBs will penetrate the Canadian market in the near future. To estimate the economic impact and costs offsets associated with the uptake and use of one or more epoetin SEBs in Canada for the treatment of anemia in chronic kidney disease. A Canada-wide epidemiological-based budget impact analysis was conducted to estimate cost outcomes under two scenarios: with and without the availability of epoetin SEB. The analysis was conducted from the perspective of the Canadian healthcare payer, over a 5-year time horizon from 2015 to 2019. Patients included in the model were those with chronic kidney disease stages 3 to 5, who have renal anemia and require treatment with erythropoietin stimulating agents. Only direct medical costs pertaining to drug acquisition of currently available erythropoietin stimulating agents in Canada were incorporated in the model. Cost of epoetin SEBs, market shares, uptake rates, and other model inputs were estimated from published sources or databases. No discounting of future costs was applied. Based on our analys...Continue Reading
References
Aug 27, 1998·The New England Journal of Medicine·A BesarabD A Goodkin
Jul 29, 2005·Clinical Nephrology·K Shalansky, J Jastrzebski
Oct 29, 2005·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Adeera LevinJoel Singer
Apr 25, 2006·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Jérôme RossertWilliam M McClellan
Nov 17, 2006·The New England Journal of Medicine·Ajay K SinghUNKNOWN CHOIR Investigators
Nov 8, 2007·JAMA : the Journal of the American Medical Association·Josef CoreshAndrew S Levey
Mar 14, 2008·Kidney International·V MenonT Greene
Apr 9, 2008·Current Medical Research and Opinion·Stefan KrivoshievUNKNOWN Epoetin Zeta Study Group
Sep 26, 2008·Kidney International. Supplement·Louise M MoistUNKNOWN Canadian Society of Nephrology
Apr 7, 2010·Advances in Therapy·Stefan KrivoshievUNKNOWN Epoetin Zeta Study Group
May 8, 2013·CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne·Paul AroraAlaa Badawi
Jun 4, 2013·Lancet·Vivekanand JhaChih-Wei Yang
Jul 23, 2013·Cost Effectiveness and Resource Allocation : C/E·Eleftheria NikolaidiMary Geitona
Jan 21, 2014·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Sean D SullivanWen-Yi Shau
Aug 26, 2014·Future Oncology·Ivo AbrahamMatti Aapro